Ending the HIV Epidemic—Part 1: Get Familiar With PrEP and PEP

Saturday, March 13, 2021

2:30 PM – 3:30 PM ET

Location: Virtual

CE: 1

Learning Level: 2
Activity Type: Knowledge-Based
ACPE Number: 0202-0000-21-023-H04-P
Number of Hours: 1

Speaker(s)

Robert M. Grant, MD, MPH

Professor of Medicine
University of California, San Francisco
San Francisco, California, United States

Disclosure: Gilead Sciences: Research Grant; MAPS Public Benefit Corporation: Research Grant

Presentation PDF View Presentation
Maria L. Lopez, PharmD, AAHIVP

President
Mission Wellness Pharmacy
San Francisco, California, United States

Disclosure: Mission Wellness Pharmacy : Ownership Interest (Status: Ongoing)

The fight against HIV gained considerable strength with the addition of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) (including non-occupational PEP). These game-changing treatments have proven their ability to prevent HIV transmission. Attend this session to understand the pharmacology behind the medication and the Centers for Disease Control and Prevention guidelines for prescribing PrEP and PEP, so you’ll be more comfortable recommending the treatments to your patients.

Learning Objectives:

Discuss the pharmacology of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV.
Identify common and significant adverse effects associated with PrEP and PEP.
Apply the appropriate Centers for Disease Control and Prevention guidelines in prescribing PrEP and PEP in the community.